Discovery and Development of Janus Kinase (JAK) Inhibitors for Inflammatory Diseases
Citations Over TimeTop 1% of 2014 papers
Abstract
The Janus kinases (JAKs) are a family of intracellular tyrosine kinases that play an essential role in the signaling of numerous cytokines that have been implicated in the pathogenesis of inflammatory diseases. As a consequence, the JAKs have received significant attention in recent years from the pharmaceutical and biotechnology industries as therapeutic targets. Here, we provide a review of the JAK pathways, the structure, function, and activation of the JAK enzymes followed by a detailed look at the JAK inhibitors currently in the clinic or approved for these indications. Finally, a perspective is provided on what the past decade of research with JAK inhibitors for inflammatory indications has taught along with thoughts on what the future may hold in terms of addressing the opportunities and challenges that remain.
Related Papers
- → Role of Janus Kinase Inhibitors in Therapy of Psoriasis(2021)62 cited
- → Understanding the efficacy of individual Janus kinase inhibitors in the treatment of ulcerative colitis for future positioning in inflammatory bowel disease treatment(2023)12 cited
- → Truncal acne following JAK inhibitor use in vitiligo with rare opportunistic fungal infections: Two case reports(2023)6 cited
- → Labile intracellular zinc is associated with 3T3 cell growth(2001)33 cited
- Intracellular pH of the turtle bladder assessed with fluorescent probes.(1987)